Article content
EBITDA and Adjusted EBITDA
Article content
EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines Adjusted EBITDA, as EBITDA, excluding stock-based compensation expense, executive long-term performance and retention bonus, restructuring costs, gain on derecognition of other obligations, fair value adjustments, transaction and other costs, impairment charges, gain on sale of building, finance income and loss or gain on sale of property, plant and equipment. Management believes EBITDA and Adjusted EBITDA are useful supplemental non-GAAP measures to determine the Company’s ability to generate cash available for operations, working capital, capital expenditures, debt repayments, interest expense and income taxes.
Article content
The following table provides a reconciliation of net and comprehensive income (loss) to EBITDA and Adjusted EBITDA:
Article content
Three months ended | Three months ended | ||
$ | $ | ||
Net and comprehensive income (loss) | 379 | (327) | |
Add back: | |||
Depreciation and amortization | 543 | 597 | |
Interest cost | 187 | 296 | |
Income tax expense | 89 | 133 | |
EBITDA | 1,198 | 699 | |
Add back: | |||
Stock-based compensation | 50 | 43 | |
Transaction and other costs | 207 | 353 | |
Executive long-term performance and retention bonus | – | 175 | |
Adjusted EBITDA | 1,455 | 1,270 | |
Attributed to: | |||
Shareholders of NeuPath Health Inc. | 1,347 | 1,133 | |
Non-controlling interest | 108 | 137 | |
1,455 | 1,270 |
Article content
Gross Margin and Gross Margin %
Article content
Management believes gross margin and gross margin % are important supplemental non-GAAP measures for evaluating operating performance and to allow for operating performance comparability from period-to-period. Gross margin is calculated as total revenue minus cost of medical services (“COMS”). Gross margin % is calculated as gross margin divided by total revenue.
Article content
The following table provides a reconciliation of total revenue to gross margin:
Article content
Three months ended | Three months ended | ||
$ | $ | ||
Clinic revenue | 20,214 | 18,046 | |
Non-clinic revenue | 1,296 | 1,289 | |
Total revenue | 21,510 | 19,335 | |
Cost of medical services | 17,555 | 15,695 | |
Gross margin(1) | 3,955 | 3,640 | |
Gross margin %(1) | 18.4% | 18.8% | |
(1) Gross margin and Gross margin % are non-IFRS measures. Please refer to Non-IFRS Financial Measures above. | |||
Article content
For further details on the results, please refer to NeuPath’s Management, Discussion and Analysis and Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2026, which are available on the Company’s website ( www.neupath.com) and under the Company’s profile on SEDAR+ ( www.sedarplus.ca).
Article content
Article content
Notice of Investor Webinar
Article content
Event
Article content
: Presentation and Q&A Webinar with NeuPath Health Inc. (NPTH)
Article content
Article content
Presentation Date & Time
Article content
: Thursday, May 14, 2026 at 10:00 AM ET / 7:00 AM PT
Article content
Article content
Webcast Registration Link:
Article content
Article content
About NeuPath
Article content
NeuPath operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain medical services. NeuPath provides improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. Working within Canada’s publicly funded healthcare system, NeuPath delivers insured medical services to help extend the appropriate care from hospitals into the community, which are complemented by select non-insured procedures to provide a comprehensive and coordinated treatment for patients. For additional information, please visit www.neupath.com.
Article content
Forward-Looking Statements
Article content
This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the Company’s expectation of continued operational improvements in 2026 and the execution of the Company’s growth opportunities are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s Annual Information Form dated March 25, 2026 filed on SEDAR
Article content
Article content
Article content
under the Company’s profile at
Article content
Article content
.
Article content
Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.
Article content
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Article content
For more information, please contact:
Article content
Jeff Zygouras
Chief Financial Officer
info@neupath.com
(905) 858-1368
Article content